TY - JOUR
T1 - Detailed optical coherence tomography angiographic short-term response of type 3 neovascularization to combined treatment with photodynamic therapy and intravitreal bevacizumab
AU - Smid, Lisette M.
AU - Vermeer, Koenraad A.
AU - Wong, King T.
AU - Martinez Ciriano, Jose P.
AU - de Jong, Jan H.
AU - Davidoiu, Valentina
AU - de Boer, Johannes F.
AU - van Velthoven, Mirjam E. J.
N1 - Funding Information: This work was supported by Health‐Holland, Top Sector Life Sciences & Health (LSHM16001); Heidelberg Engineering; the Dutch Technology Foundation STW (12822); and the Netherlands Organisation for Health Research and Development ZonMW (91212061). Publisher Copyright: © 2020 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation
PY - 2020/6/29
Y1 - 2020/6/29
N2 - PurposeTo explore the short‐term vascular and structural changes of type 3 neovascularization using optical coherence tomography angiography (OCT‐A) when treated with a combination of photodynamic therapy (PDT) and intravitreal bevacizumab (IVB), and to evaluate the course of different sequences of the combined therapies.MethodsThirty eyes of 29 treatment‐naïve patients with a type 3 neovascularization were included in this prospective observational cohort study. They were all treated with PDT and IVB 2 weeks apart, starting either with PDT (PDT‐first group) or IVB (IVB‐first group). Optical coherence tomography angiography (OCT‐A) imaging was performed at week 0, 2, 4 and 18, and best corrected visual acuity (BCVA) at week 0 and 18. Vascular, structural and functional features were graded and analysed over time.ResultsIn all patients, at all follow‐up visits, vascular and structural features were significantly more often decreased or resolved than unchanged or increased. Best corrected visual acuity (BCVA) significantly improved at 18 weeks. Vascular, structural and functional outcomes were all slightly better in the PDT‐first group compared to the IVB‐first group, although not statistically significant.ConclusionCombined treatment of PDT and IVB is effective in short‐term for type 3 neovascularization based on vascular and structural features. Initial treatment with PDT tended to be more effective than with IVB.
AB - PurposeTo explore the short‐term vascular and structural changes of type 3 neovascularization using optical coherence tomography angiography (OCT‐A) when treated with a combination of photodynamic therapy (PDT) and intravitreal bevacizumab (IVB), and to evaluate the course of different sequences of the combined therapies.MethodsThirty eyes of 29 treatment‐naïve patients with a type 3 neovascularization were included in this prospective observational cohort study. They were all treated with PDT and IVB 2 weeks apart, starting either with PDT (PDT‐first group) or IVB (IVB‐first group). Optical coherence tomography angiography (OCT‐A) imaging was performed at week 0, 2, 4 and 18, and best corrected visual acuity (BCVA) at week 0 and 18. Vascular, structural and functional features were graded and analysed over time.ResultsIn all patients, at all follow‐up visits, vascular and structural features were significantly more often decreased or resolved than unchanged or increased. Best corrected visual acuity (BCVA) significantly improved at 18 weeks. Vascular, structural and functional outcomes were all slightly better in the PDT‐first group compared to the IVB‐first group, although not statistically significant.ConclusionCombined treatment of PDT and IVB is effective in short‐term for type 3 neovascularization based on vascular and structural features. Initial treatment with PDT tended to be more effective than with IVB.
KW - anti-VEGF
KW - intraretinal cysts
KW - intraretinal neovascularization
KW - intravitreal bevacizumab
KW - optical coherence tomography angiography
KW - photodynamic therapy
KW - retinal choroidal anastomosis
KW - type 3 neovascularization
UR - http://www.scopus.com/inward/record.url?scp=85087302932&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/aos.14525
DO - https://doi.org/10.1111/aos.14525
M3 - Article
C2 - 32602240
SN - 1755-375X
VL - 99
SP - 207
EP - 214
JO - Acta ophthalmologica
JF - Acta ophthalmologica
IS - 2
ER -
